BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 27020109)

  • 1. Feasibility and Initial Dosimetric Findings for a Randomized Trial Using Dose-Painted Multiparametric Magnetic Resonance Imaging-Defined Targets in Prostate Cancer.
    Bossart EL; Stoyanova R; Sandler K; Studenski M; Orman A; Abramowitz M; Pollack A
    Int J Radiat Oncol Biol Phys; 2016 Jun; 95(2):827-34. PubMed ID: 27020109
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A treatment planning and acute toxicity comparison of two pelvic nodal volume delineation techniques and delivery comparison of intensity-modulated radiotherapy versus volumetric modulated arc therapy for hypofractionated high-risk prostate cancer radiotherapy.
    Myrehaug S; Chan G; Craig T; Weinberg V; Cheng C; Roach M; Cheung P; Sahgal A
    Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):e657-62. PubMed ID: 22245189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In Silico Trial of MR-Guided Midtreatment Adaptive Planning for Hypofractionated Stereotactic Radiation Therapy in Centrally Located Thoracic Tumors.
    Henke LE; Kashani R; Hilliard J; DeWees TA; Curcuru A; Przybysz D; Green O; Robinson CG; Bradley JD
    Int J Radiat Oncol Biol Phys; 2018 Nov; 102(4):987-995. PubMed ID: 29953910
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dominant intraprostatic lesion boosting in sexual-sparing radiotherapy of prostate cancer: A planning feasibility study.
    Ciabatti S; Ntreta M; Buwenge M; Gaudiano C; Sessagesimi E; Romani F; Angelini AL; Cammelli S; Macchia G; Deodato F; Zamagni A; Golfieri R; Morganti AG; Cilla S
    Med Dosim; 2019 Winter; 44(4):356-364. PubMed ID: 30955990
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Focal boost to residual gross tumor volume in brachytherapy for cervical cancer-A feasibility study.
    Thiruthaneeswaran N; Groom N; Lowe G; Bryant L; Hoskin PJ
    Brachytherapy; 2018; 17(1):181-186. PubMed ID: 29153466
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Volumetric modulated arc therapy planning for primary prostate cancer with selective intraprostatic boost determined by 18F-choline PET/CT.
    Kuang Y; Wu L; Hirata E; Miyazaki K; Sato M; Kwee SA
    Int J Radiat Oncol Biol Phys; 2015 Apr; 91(5):1017-25. PubMed ID: 25832692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the dosimetric impact of non-exclusion of the rectum from the boost PTV in IMRT treatment plans for prostate cancer patients.
    Kassim I; Dirkx ML; Heijmen BJ
    Radiother Oncol; 2009 Jul; 92(1):62-7. PubMed ID: 19278745
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intensity-modulated radiation therapy for pancreatic and prostate cancer using pulsed low-dose rate delivery techniques.
    Li J; Lang J; Wang P; Kang S; Lin MH; Chen X; Chen F; Guo M; Chen L; Ma CM
    Med Dosim; 2014; 39(4):330-6. PubMed ID: 25087084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intensity modulated radiation therapy dose painting for localized prostate cancer using ¹¹C-choline positron emission tomography scans.
    Chang JH; Lim Joon D; Lee ST; Gong SJ; Anderson NJ; Scott AM; Davis ID; Clouston D; Bolton D; Hamilton CS; Khoo V
    Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):e691-6. PubMed ID: 22658218
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neurovascular bundle-sparing radiotherapy for prostate cancer using MRI-CT registration: A dosimetric feasibility study.
    Cassidy RJ; Yang X; Liu T; Thomas M; Nour SG; Jani AB
    Med Dosim; 2016 Winter; 41(4):339-343. PubMed ID: 27745996
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Importance of protocol target definition on the ability to spare normal tissue: an IMRT and 3D-CRT planning comparison for intraorbital tumors.
    Hein PA; Gladstone DJ; Bellerive MR; Hug EB
    Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1540-8. PubMed ID: 16029816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Postoperative radiotherapy for prostate cancer: a comparison of four consensus guidelines and dosimetric evaluation of 3D-CRT versus tomotherapy IMRT.
    Malone S; Croke J; Roustan-Delatour N; Belanger E; Avruch L; Malone C; Morash C; Kayser C; Underhill K; Li Y; Malone K; Nyiri B; Spaans J
    Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):725-32. PubMed ID: 22444999
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Magnetic resonance imaging-based treatment planning for prostate cancer: Use of population average tissue densities within the irradiated volume to improve plan accuracy.
    Hu Y; Zhao W; Du D; Wooten HO; Olsen JR; Gay HA; Michalski JM; Mutic S
    Pract Radiat Oncol; 2015; 5(4):248-56. PubMed ID: 25649539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessing the Dosimetric Accuracy of Magnetic Resonance-Generated Synthetic CT Images for Focal Brain VMAT Radiation Therapy.
    Paradis E; Cao Y; Lawrence TS; Tsien C; Feng M; Vineberg K; Balter JM
    Int J Radiat Oncol Biol Phys; 2015 Dec; 93(5):1154-61. PubMed ID: 26581151
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MRI-based treatment planning for radiotherapy: dosimetric verification for prostate IMRT.
    Chen L; Price RA; Wang L; Li J; Qin L; McNeeley S; Ma CM; Freedman GM; Pollack A
    Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):636-47. PubMed ID: 15380601
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of
    Jani AB; Schreibmann E; Rossi PJ; Shelton J; Godette K; Nieh P; Master VA; Kucuk O; Goodman M; Halkar R; Cooper S; Chen Z; Schuster DM
    J Nucl Med; 2017 Mar; 58(3):412-418. PubMed ID: 27609792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Knowledge-Based Assessment of Focal Dose Escalation Treatment Plans in Prostate Cancer.
    van Schie MA; Janssen TM; Eekhout D; Walraven I; Pos FJ; de Ruiter P; Kotte ANTJ; Monninkhof EM; Kerkmeijer LGW; Draulans C; de Roover R; Haustermans K; Kunze-Busch M; Smeenk RJ; van der Heide UA
    Int J Radiat Oncol Biol Phys; 2020 Nov; 108(4):1055-1062. PubMed ID: 32629078
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intensity-modulated radiotherapy for soft tissue sarcoma of the thigh.
    Hong L; Alektiar KM; Hunt M; Venkatraman E; Leibel SA
    Int J Radiat Oncol Biol Phys; 2004 Jul; 59(3):752-9. PubMed ID: 15183478
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Helical tomotherapy vs. intensity-modulated proton therapy for whole pelvis irradiation in high-risk prostate cancer patients: dosimetric, normal tissue complication probability, and generalized equivalent uniform dose analysis.
    Widesott L; Pierelli A; Fiorino C; Lomax AJ; Amichetti M; Cozzarini C; Soukup M; Schneider R; Hug E; Di Muzio N; Calandrino R; Schwarz M
    Int J Radiat Oncol Biol Phys; 2011 Aug; 80(5):1589-600. PubMed ID: 21167651
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of Daily Plan Adaptation in MR-Guided Stereotactic Ablative Radiation Therapy for Adrenal Metastases.
    Palacios MA; Bohoudi O; Bruynzeel AME; van Sörsen de Koste JR; Cobussen P; Slotman BJ; Lagerwaard FJ; Senan S
    Int J Radiat Oncol Biol Phys; 2018 Oct; 102(2):426-433. PubMed ID: 29902559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.